Based on biopsy findings, aGleason scoreis used to describe the aggressiveness of the tumor.
Screening Tests
The vast majority of prostate cancers are discovered on screening tests before anysigns and symptomsoccur.
Screening tests cannot diagnose prostate cancer, but they can help direct further testing.
Illustration by Verywell
PSA is a protein thats secreted by prostate cells, and it is very specific for prostate tissue.
A PSA level that is increasing is often more meaningful than the absolute value of the test.
Similarly, prostate cancer may be present even with a level less than 4 ng/ml.
Get our printable guide for your next healthcare provider’s appointment to help you ask the right questions.
A DRE can be somewhat uncomfortable and may cause a sense that you gotta urinate.
This test is safe and it only takes a few minutes.
Biomarkers are substances that are produced either by prostate cancer or by the body when prostate cancer is present.
Illustration by Verywell
Have a conversation with your healthcare provider about your recommended testing schedule in relation to your overall risk profile.
Get our printable guide for your next healthcare provider’s appointment to help you ask the right questions.
Before a transrectal ultrasound, an enema is given.
During the test, a thin, lubricated ultrasound probe is inserted into the rectum.
Discomfort is usually mild and consists of a feeling of fullness in the rectum.
If a TRUS is abnormal, a biopsy is needed to determine if abnormal appearing regions are cancerous.
This is usually an outpatient procedure.
The area of the rectum where the biopsies will be done is numbed locally with lidocaine.
The procedure takes roughly 20 to 30 minutes.
Warm soaks and compresses may alleviate discomfort.
Multiparametric MRI (mp-MRI) is a special punch in of MRI used to detect abnormalities in prostate tissue.
The procedure is similar to the random 12-core biopsy, but an MRI is done in advance.
Targeted biopsies are limited to abnormal appearing regions.
Its thought that this approach may help reduce the risk of overdiagnosis and overtreatment of prostate cancer.
This procedure is not available at all cancer centers.
Its thought that selective biopsies will improve the accuracy of diagnosis.
As with multiparametric MRI, the procedure is not available everywhere.
This test measures the ratio of PCA3 RNA to PSA RNA in the urine.
Depending on the results, a repeatbiopsymay be recommended.
Some prostate cancers are non-aggressive and would not cause a problem if left alone.
Additional tests may be done to further stage the tumor.
Prostate cancer has a strong tendency to spread to bones.
This is broken down into:
T3: The tumor has spread beyond the prostate to nearby tissues.
In a case when a radical prostatetomy is performed, the cancer is confined to prostate.
The cells look very normal (grade group 1).
PSA is less than 10.
Stage II:These tumors have not spread beyond the prostate gland and PSA is less than 20.
Stage IV:Stage IV prostate cancers have spread beyond the prostate.
Risk Groups
Prostate cancers are also broken down into risk groups.
Tests for Recurrence
After prostate cancer is treated, some cancers can recur.
However, its important to know that a number of other conditions can cause similar symptoms.
While some of these conditions are easily distinguished from prostate cancer, others pose more of a challenge.
The scores are added together: the higher the score, the more serious the cancer.
National Cancer Institute.Prostate cancer screening (PDQ)patient version.
2018;319(18):1914-1931. doi:10.1001/jama.2018.3712
American Cancer Society.Screening tests for prostate cancer.
American Cancer Society.Your prostate pathology report: cancer (adenocarcinoma).
National Library of Medicine: DailyMed.Axuminfluciclovine f-18 injection, solution[drug label].
National Cancer Institute.Genetics of prostate cancer (PDQ)health professional version.
American Cancer Society.Prostate cancer stages.
National Comprehensive Cancer web link.NCCN guidelines: prostate cancer: early stage.
2015;92(8):683-688.
Prostate Cancer Foundation.Gleason score and grade group.
American Cancer Society.Tests to diagnose and stage prostate cancer.
2018;119:23-31. doi:10.1016/j.urology.2018.04.026
National Cancer Institute.Prostate cancer screening (PDQ)health professional version.
